

Resource Summary Report

Generated by [NIF](#) on Sep 21, 2026

SW780

RRID:CVCL_1728

Type: Cell Line

Proper Citation

RRID:CVCL_1728

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1728

Proper Citation: RRID:CVCL_1728

Description: Cell line SW780 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Bladder carcinoma

Defining Citation: [PMID:571047](#), [PMID:833871](#), [PMID:924690](#), [PMID:3518877](#), [PMID:6244232](#), [PMID:6744315](#), [PMID:7459858](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:22460905](#), [PMID:24018021](#), [PMID:24035680](#), [PMID:24367658](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25997541](#), [PMID:26589293](#), [PMID:27189164](#), [PMID:27270441](#), [PMID:27397505](#), [PMID:29732388](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31395879](#), [PMID:35839778](#)

Comments: Population: Caucasian., From: Scott and White Clinic; Temple; USA., Part of: UBC-40 urothelial bladder cancer cell line index., Part of: TCGA-110-CL cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Part of: BLA-40 bladder carcinoma cell line panel.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: SW780

Synonyms: SW-780, SW 780

Cross References: BTO:BTO_0006307, CLO:CLO_0009199, EFO:EFO_0002371, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706,

ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-2169, BioSample:SAMN03473242, BioSample:SAMN10988174, cancercellines:CVCL_1728, CCRID:3101HUMTCHu219, Cell_Model_Passport:SIDM01160, ChEMBL-Cells:ChEMBL3308468, ChEMBL-Targets:ChEMBL1075595, CLS:305098, Cosmic:687457, Cosmic:1285128, Cosmic:1285990, Cosmic:1819323, Cosmic:2037958, Cosmic:2050464, Cosmic:2057457, Cosmic:2444257, Cosmic:2686117, Cosmic:2700998, Cosmic-CLP:687457, DepMap:ACH-000384, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:687457, GEO:GSM136235, GEO:GSM827294, GEO:GSM887678, GEO:GSM888770, GEO:GSM1374936, GEO:GSM1574556, GEO:GSM1670512, GEO:GSM2143918, GEO:GSM2143919, GEO:GSM2143920, IARC_TP53:27584, IGRhCellID:SW780, LiGeA:CCLE_886, LINCS_LDP:LCL-1718, PharmacDB:SW780_1545_2019, PRIDE:PXD030304, Progenetix:CVCL_1728, PubChem_Cell_line:CVCL_1728, Ubigen:YC-C138, Wikidata:Q54971204

ID: CVCL_1728

Record Creation Time: 20220427T221615+0000

Record Last Update: 20260920T005912+0000

Ratings and Alerts

No rating or validation information has been found for SW780.

No alerts have been found for SW780.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 131 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Pece A, et al. (2026) Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarker. *Molecular oncology*, 20(3), 823.

Sun W, et al. (2026) Reconstruction of T cell infiltration in an osteosarcoma PDX-organoid interactive biobank for personalized immunotherapy. *Cell reports. Medicine*, 7(3), 102644.

Stuckey JI, et al. (2026) Covalent PPAR γ inverse agonism by FX-909 reveals mechanistic insights into therapeutic targeting of PPAR γ /RXR γ -activated urothelial carcinoma. *Cell chemical biology*, 33(6), 837.

Duan X, et al. (2025) Preclinical Evaluation of an Al18F-Radiolabeled Bicyclic Peptide Targeting Nectin-4. *Molecular pharmaceutics*, 22(1), 221.

Yu Y, et al. (2025) A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer. *Cancer research*, 85(12), 2288.

Wang X, et al. (2025) PIN1 Prolyl Isomerase Promotes Initiation and Progression of Bladder Cancer through the SREBP2-Mediated Cholesterol Biosynthesis Pathway. *Cancer discovery*, 15(3), 633.

Yan Y, et al. (2024) IMP2 drives chemoresistance by repressing cisplatin-induced apoptosis and ferroptosis via activation of IPO4 and SLC7A11 under hypoxia in bladder cancer. *Cancer cell international*, 24(1), 386.

Zhang H, et al. (2024) Role of Forkhead Box P3 in IFN γ -Mediated PD-L1 Expression and Bladder Cancer Epithelial-to-Mesenchymal Transition. *Cancer research communications*, 4(8), 2228.

Guo X, et al. (2023) Long non-coding RNA LINC00336 as an independent prognostic indicator and an oncogenic lncRNA in bladder cancer. *Archives of medical science : AMS*, 19(2), 478.

Park WY, et al. (2023) Apoptosis-induced nuclear expulsion in tumor cells drives S100a4-mediated metastatic outgrowth through the RAGE pathway. *Nature cancer*, 4(3), 419.

Li P, et al. (2023) Characterization of circSCL38A1 as a novel oncogene in bladder cancer via targeting ILF3/TGF- β 2 signaling axis. *Cell death & disease*, 14(1), 59.

Zhang L, et al. (2023) The m6A Reader YTHDF2 Promotes Bladder Cancer Progression by Suppressing RIG-I-Mediated Immune Response. *Cancer research*, 83(11), 1834.

Qiu H, et al. (2023) KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer. *Cancer research*, 83(6), 814.

Chen L, et al. (2023) PABPN1 regulates mRNA alternative polyadenylation to inhibit bladder cancer progression. *Cell & bioscience*, 13(1), 45.

Okano F, et al. (2023) Identification of Membrane-expressed CAPRIN-1 as a Novel and Universal Cancer Target, and Generation of a Therapeutic Anti-CAPRIN-1 Antibody TRK-950. *Cancer research communications*, 3(4), 640.

Mao M, et al. (2022) Oncogenic E3 ubiquitin ligase NEDD4 binds to KLF8 and regulates the microRNA-132/NRF2 axis in bladder cancer. *Experimental & molecular medicine*, 54(1), 47.

Lyu X, et al. (2022) Identification of immuno-infiltrating MAP1A as a prognosis-related biomarker for bladder cancer and its ceRNA network construction. *Frontiers in oncology*, 12, 1016542.

Gu L, et al. (2022) Integrated Analysis and Identification of Critical RNA-Binding Proteins in Bladder Cancer. *Cancers*, 14(15).

Li F, et al. (2022) FGFBP1 as a potential biomarker predicting bacillus Calmette-Guérin response in bladder cancer. *Frontiers in immunology*, 13, 954836.

Wang X, et al. (2022) A novel deep learning segmentation model for organoid-based drug screening. *Frontiers in pharmacology*, 13, 1080273.